我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

强化他汀治疗对择期PCI患者冠脉无复流及血浆APN与炎性因子的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第2期
页码:
189-192
栏目:
临床研究
出版日期:
2012-04-25

文章信息/Info

Title:
Intensive atorvastatin therapy decreases plasma hs-CRP and increases plasma adiponectin in patients undergoing elective percutaneous coronary intervention
作者:
常快乐; 王海昌; 廉 坤; 贾 敏; 刘 毅; 马新亮; 陶 凌
(第四军医大学西京医院心血管内科，陕西 西安 710032)
Author(s):
CHANG Kuai-le;  WANG Hai-chang;  LIAN Kun;  JIA Min;  LIU Yi;  MA Xin-liang;  TAO Ling
(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
强化他汀治疗; 脂联素; 无复流现象; 经皮冠状动脉介入治疗
Keywords:
intensive atorvastatin therapy;  adiponectin;  no/slow flow;  percutaneous coronary intervention
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:观察强化他汀治疗对择期经皮冠状动脉介入治疗（PCI）患者术中出现无复流风险及其血浆脂联素（APN）、血清高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、炎性因子高敏C反应蛋白(hs-CRP)的影响。方法：70例择期PCI患者随机分为强化他汀组（强化组，n=35）及常规他汀组（常规组，n=35），强化组阿托伐他汀每日80 mg，2 d术前进行预处理，2 d后每日40 mg，服1月，常规组术前每日20 mg， 2 d，术后长期服用。分别检测术前及术后1月、3月hs-CRP、HDL-C、LDL-C、APN；观察术中无复流的发生率；主要终点是30 d内的主要不良心脏事件(MACE；死亡，心肌梗死或计划外的血管重建)。结果：两组均未出现MACE，均无明显不良反应。1月后两组APN、HDL-C均有上升，强化组APN：（8±4）mg/L，常规组：（6±3）mg/L；强化组上升明显（P<0.05）。两组hs-CRP、LDL-C均有下降，强化组hs-CRP：（3.2±2.1）mg/L，常规组：（4.5±2.3）mg/L；强化组显著性下降（P<0.05）；术前与术后比较差异有统计学意义(P<0.05)。强化组术中无复流3例，常规组5例，两组差异未达到统计学意义。结论：强化他汀治疗能够降低择期PCI患者血浆炎性因子水平，升高血浆APN水平。
Abstract:
AIM:To investigate the effect of intensive atorvastatin therapy in patients undergoing percutaneous coronary intervention (PCI). METHODS: Seventy patients undergoing elective PCI were randomly divided into intensive atorvastatin therapy group (35 patients) and moderate atorvastatin therapy group (35 patients). The patients in the intensive group were given atorvastatin (80 mg/day) for 2 days before PCI followed by 40 mg/day for 30 days after PCI. Patients in the moderate group were given atorvastatin (20 mg/day) for 2 days before PCI followed by 20 mg/day for 30 days after PCI. The 30-day incidence of major adverse cardiac events (MACE) and the incidence of slow flow/no reflow were recorded. Plasma levels of hs-CRP, HDL-C, LDL-C, adiponectin (APN) and myocardial injury markers (CK-MB and cTnI) were tested in the two groups before as well as 1 and 3 months after PCI. RESULTS: No occurrence of MACE and no severe adverse effects were found in the two groups. Plasma APN significantly increased and hs-CRP decreased in the intensive group compared with those in the moderate group ［APN: (8±4) mg/L vs. (6±3) mg/L; hs-CRP: (3.2±2.1) mg/L vs. (4.5±2.3) mg/L, P<0.05］ after 1 month. The incidence of slow flow/no reflow was 3/35 in intensive group and 5/35 in moderate group with no statistical significance between groups. CONCLUSION: Intensive atorvastatin therapy significantly decreases plasma hs-CRP and increases plasma adiponectin in patients undergoing elective PCI.

参考文献/References

[1]Di Sciascio G,Patti G,Pasceri V,et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial[J].J Am Coll Cardiol,2009,54(6):558-565.

[2]Briguori C,Visconti G,Focaccio A,et al.Novel approaches for preventing or limiting events (Naples) II trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J].J Am Coll Cardiol,2009,54(23):2157-2163.

[3]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcom es in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA ACS randomized trial[J].J Am Colt Caraiol,2007,49(12):1272-1278.

[4]Lewicki M,Kotyla P,Jankiewicz-Ziobro K,et al.The role of adiponectin in atherosclerosis[J].Pol Merkur Lekarski,2006,20(118):494-496.

[5]Luis M,Blanco-Colio,Jose L,et al.Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk[J].European Journal of Pharmacology,2008,586(1-3):259-265.

[6]Sako H,Miura S,Saku K.Significance of changes in plasma adiponectin concentration after the implantation of stents in patients with stable angina[J].J Cardiol,2008,52(1):17-23.

[7]Wang CY,Liu PY,Liao JK.Pleiotropic effects of statin therapy:molecular mechanisms and clinical results[J].Trends Mol Med,2008,14(1):37-44.

[8]Otake H,Shite J,Shinke T,et al.Relation between plasma adiponectin,high- sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome[J]. Am J Cardiol,2008,101(1):1-7.

[9]Nakamura T,Kodama Y,Takano H,et al.Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia[J].Atherosclerosis,2007,193(2):449-451.

[10]Sugiyama S,Fukushima H,Kugiyama K,et al.Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease[J]. Atherosclerosis,2007,194(2):43-51.

[11]Cao Y,Tao L,Yuan Y,et al.Endothelial dysfunction in adiponectin deficiency and its mechanisms involved[J].J Mol Cell Cardiol,2009,46(3):413-419.

[12]Plant S,Shand B,Elder P,et al.Adiponeetin attenuates endothelial dysfunction induced by oxidized low density lipoproteins[J].Dial Vasc Dis Res,2008,5(2):102-108.

备注/Memo

备注/Memo:
收稿日期：2011-10-31.基金项目：国家高技术研究发展计划项目资助(863计划，2009AA02乙104) 通讯作者：王海昌，主任医师，主要从事冠心病基础及介入治疗研究 Email：wanghc@fmmu.edu.cn 共同通讯作者：陶凌，主任医师，主要从事冠心病心肌缺血再灌注损伤研究 Email：Lingtao2006@gmail.com 作者简介：常快乐，硕士生 Email：changkle@163.com
更新日期/Last Update: 2012-04-01